



FOR IMMEDIATE RELEASE

July 29, 2026

Listed Company Name:	Eisai Co., Ltd.
Representative:	Haruo Naito Representative Corporate Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange
Inquiries:	Teruyuki Masaka Vice President, Corporate Communications Phone +81-3-3817-5120

Revenue of LEQEMBI® (Preliminary Basis)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta antibody "LEQEMBI®" (generic name: lecanemab) was JPY 29.3 billion for the first quarter of fiscal year 2026 (April 1, 2026 – June 30, 2026). In the same period of the previous fiscal year, the global revenue was JPY 23.1 billion, including the impact of stockpiling by distributors (estimated JPY 5.3 billion) in China.

By major markets, revenue came to JPY 15.4 billion in the United States, JPY 6.1 billion in Japan, and JPY 4.8 billion in China (in the same period last year: JPY 9.1 billion in the United States, JPY 5.5 billion in Japan, and JPY 7.7 billion in China).

This information is being disclosed in conjunction with today's announcement of the financial results for the second quarter of 2026 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai's financial results for the first quarter of fiscal year 2026, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled for August 3, 2026.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
